What clinical trials has Sunosi (solriamfetol) been studied in?
Sunosi (solriamfetol) has been evaluated in clinical trials focused on improving excessive daytime sleepiness in two main sleep disorders:
- Obstructive sleep apnea (OSA)
- Narcolepsy
The studies evaluated whether solriamfetol can improve wakefulness and reduce sleepiness scores compared with placebo, using standardized measures used in sleep research.
What conditions does Sunosi target in clinical research?
Clinical development for Sunosi has centered on patients who have “excessive daytime sleepiness,” a core symptom in both:
- OSA, where disrupted sleep from breathing events drives daytime sleepiness
- Narcolepsy, a neurological sleep disorder with persistent sleepiness and sleep-wake dysregulation
How do researchers measure results in Sunosi studies?
Trials typically use validated sleepiness scales to quantify changes from baseline to later time points, comparing solriamfetol against placebo. These endpoints are designed to capture clinically meaningful improvements in daytime alertness.
What dosing and study designs were used?
Sunosi clinical research includes randomized, placebo-controlled studies assessing different solriamfetol doses. Participants are followed for changes in sleepiness/alertness outcomes over the course of the trial, with safety monitoring throughout.
What side effects do clinical trials report for Sunosi?
As with most wakefulness-promoting agents, Sunosi safety monitoring in clinical research includes common adverse events and effects that are especially relevant to stimulatory medications. Reported safety findings are based on trial adverse-event reporting and laboratory/vital-sign monitoring during the controlled study period.
Where can I find trial and regulatory information on Sunosi?
For a consolidated view that can also point you to patent and market exclusivity context alongside medication research coverage, DrugPatentWatch.com tracks drug background and related materials for Sunosi here: https://www.drugpatentwatch.com/p/sunosi/
What to check if you want the most detailed clinical data
If you’re looking for the exact trial designs, inclusion criteria, endpoints, and results tables, the most reliable approach is to match:
- the disorder (OSA vs narcolepsy),
- the trial identifiers (e.g., NCT numbers),
- and the study endpoints (sleepiness/alertness scales and safety assessments).
If you tell me whether you mean OSA trials or narcolepsy trials (and whether you want Phase 2, Phase 3, or results), I can narrow the clinical research summary to the relevant program.
Sources
- DrugPatentWatch.com – Sunosi (solriamfetol)